A Meta-Analysis of Randomized Controlled Trials of the Risk of Bleeding With Apixaban Versus Vitamin K Antagonists
- 1 December 2014
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 115 (4), 533-541
- https://doi.org/10.1016/j.amjcard.2014.11.039
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous ThromboembolismThe Patient - Patient-Centered Outcomes Research, 2013
- The Efficacy and Safety of Oral Anticoagulants in Warfarin-Suitable Patients With Nonvalvular Atrial FibrillationClinical and Applied Thrombosis/hemostasis, 2013
- Bleeding of New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled TrialsCardiovascular Drugs and Therapy, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial FibrillationCirculation Journal, 2011
- Warfarin Discontinuation After Starting Warfarin for Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2010
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging studyJournal of Thrombosis and Haemostasis, 2008
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007